CDR2L

Across TCGA pan-cancer cohorts, CDR2L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDR2L data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDR2L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CDR2L expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, GBM, and HNSC are the cancer types where CDR2L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	II,III,IV	0.585	0.291	.001	28	view →
GBM	OS	Median	All	0.409	0.629	.003	21	view →
HNSC	OS	Quartile	All	0.839	0.523	.005	18	view →
LUAD	OS	Tertile	III,IV	0.342	0.801	.003	13	view →
LSCC	DFS	Tertile	All	0.848	1.000	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDR2L–PDAC (DFS)

Open the PDAC breakdown →